ESR1 and breast cancer: Indeed, the high levels of ATM in ERα-negative BC suggest that this DDR kinase could represent an interesting drug target in ERα-negative BCs: the usage of specific ATM inhibitors in combination with chemotherapeutic agents and/or radiotherapy might achieve more effective clinical benefits as the treatment might enhance tumor sensitivity to both chemotherapeutics and radiotherapy [10].